NCT02749383

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis

A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Amorepacific Corporation · Industry
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study is a Phase II, single center, randomized, double-blind, placebo-controlled study in male and female subjects, aged ≥ 19 years with mild to moderate seborrheic dermatitis of the face. All subjects will receive BID topical applications of PAC-14028 cream or vehicle for up to 4 weeks.

Conditions

• Seborrheic Dermatitis

Interventions

Type	Name	Description
DRUG	PAC-14028 cream 0.3%	Topical application
DRUG	PAC-14028 cream 1.0%	Topical application
DRUG	PAC-14028 cream vehicle	Topical application

Timeline

• Start date: 2014-02-01
• Primary completion: 2014-12-01
• Completion: 2015-10-01
• First posted: 2016-04-25
• Last updated: 2016-04-25